Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will be presenting at the H.C. Wainwright Global Investment Conference, taking place May 23-26, 2022, and the Jefferies Global Healthcare Conference, taking place June 8-10, 2022.
Ikena CEO Mark Manfredi, Ph.D., will present a corporate update at the H.C. Wainwright Global Investment Conference and management will attend virtually. They will also participate in a fireside chat at the Jefferies Global Healthcare Conference and will attend the conference live in New York City.
Details can be found below:
| H.C Wainwright Global Investment Conference |
| Corporate Presentation |
| Date: May 25, 2022, 11:30 a.m. ET |
| Webcast Link |
| Jefferies Global Healthcare Conference |
| Fireside Chat |
| Date: June 9, 2022, 10:00 a.m. ET |
| Webcast Link |
The presentation webcasts will be available on the Company’s Events & Presentations page on their website at www.ikenaoncology.com.
About Ikena Oncology
Ikena OncologyTM is focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer. The Company’s lead targeted oncology program, IK-930, is a TEAD inhibitor addressing the Hippo signaling pathway, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company’s ongoing discovery research spans other targets in the Hippo pathway as well as the RAS signaling pathway. Additional programs targeting the tumor microenvironment and immune signaling are in the clinic, including IK-175, an aryl hydrocarbon receptor antagonist, which is being developed in collaboration with Bristol Myers Squibb. Ikena’s pipeline is built on addressing genetically defined or biomarker-driven cancers and developing therapies that can serve specific patient populations in need of new therapeutic options. To learn more, visit www.ikenaoncology.com or follow us on Twitter and LinkedIn.
Investor Contact:
Rebecca Cohen
Ikena Oncology
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Gwen Schanker
LifeSci Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.11 |
| Daily Change: | -0.03 -2.63 |
| Daily Volume: | 51,927 |
| Market Cap: | US$53.570M |
December 23, 2024 November 07, 2024 August 08, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
